Table 2. Frequency of AEs, maximum AE grade (G) after treatment, Mf and CFA status per participant by treatment arm and gender.
| Treatment arm | Gender | Total treated and followed up | Any AE n (%) | G1 n (%) | G2 n (%) | G3/4/SAE n (%) | Mf+ n (%) | CFA + n (%) |
|---|---|---|---|---|---|---|---|---|
| DA | Female | 993 | 187 (19) | 162 (16) | 25 (3) | 0 | 31 (3) | 192 (19) |
| Male | 1070 | 176 (16) | 152 (14) | 24 (2) | 0 | 62 (6) | 279 (26) | |
| Total | 2063 | 363 (18) | 314 (15) | 49 (2) | 0 | 93 (5) | 471 (23) | |
| IDA | Female | 1091 | 227(21) | 196 (18) | 31 (3) | 0 | 31 (3) | 196(18) |
| Male | 1246 | 249 (20) | 222 (18) | 27 (2) | 0 | 74 (6) | 321(26) | |
| Total | 2337 | 476 (20) | 418 (18) | 58 (2) | 0 | 105 (4) | 517 (22) |
AE: adverse event; DA: diethylcarbamazine and albendazole; IDA: ivermectin, diethylcarbamazine and albendazole; CFA: circulating filarial antigen; Mf, microfilariae. The maximum AE grade (G)/participant was used. Grade 1 (G1) = mild and Grade 2 (G2) = moderate AEs.